A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Jilin Cancer Hospital ( Site 1163), Changchun

Shanghai Tenth People's Hospital ( Site 1170), Shanghai

Fudan University Shanghai Cancer Center ( Site 1176), Shanghai

Changzhou Cancer Hospital-Department of Oncology ( Site 1183), Changzhou

Affiliated Hospital of Jiangnan University(Wuxi Fourth People's Hospital ) ( Site 1185), Wuxi

The Second Affiliated Hospital of Anhui Medical University ( Site 1179), Hefei

Jinan Central Hospital ( Site 1167), Jinan

Tianjin Medical University Cancer Institute and Hospital ( Site 1161), Tianjin

Zhejiang Cancer Hospital ( Site 1180), Hangzhou

Sir Run Run Shaw Hospital-Medical Oncology ( Site 1173), Hangzhou

West China Hospital Sichuan University ( Site 1172), Chengdu

Fujian Province Cancer Hospital ( Site 1178), Fuzhou

Chongqing Cancer Hospital ( Site 1151), Chongqing

Xiangya Hospital Central South University ( Site 1171), Changsha

Hunan Cancer Hospital ( Site 1174), Changsha

The Third Xiangya Hospital of Central South University ( Site 1175), Changsha

Wuhan Union Hospital Cancer Center ( Site 1162), Wuhan

Hubei Cancer Hospital ( Site 1152), Wuhan

Sun Yat-Sen University Cancer Center ( Site 1150), Guangzhou

Southern Medical University Nanfang Hospital ( Site 1154), Guangzhou

The Sixth Affiliated Hospital of Sun Yat-sen University ( Site 1159), Guangzhou

Guangxi Medical University Affiliated Tumor Hospital ( Site 1158), Nanning

Hainan General Hospital ( Site 1177), Haikou

Yunnan Province Cancer Hospital-Colorectal surgery ( Site 1169), Kunming